209P Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors

S.J. Klempner,M. Beeram, D. Sabanathan, A. Chan,E. Hamilton,S. Loi,D-Y. Oh,L.A. Emens,A. Patnaik, J.E. Kim, Y.H. Park, V. Odegard, S. Hamke, G. Jang, C. Jacquemont, N. Hunder,S.A. Piha-Paul

Annals of Oncology（2021）

引用 9|浏览7

暂无评分

摘要

SBT6050 comprises a TLR8 agonist linker-payload conjugated to a HER2-directed antibody and is designed to activate myeloid cells in tumors expressing moderate to high levels of HER2. TLR8 agonism directly activates myeloid cells and secondarily activates NK and T cells, inducing a broad spectrum of anti-tumor immune mechanisms.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要